Drug
Mycophenolate clinical trials
- studies test it
- 50
- open now
- 3
- in phase 3
- 18
- first study started
- 2002
Keep track of what changes. Save the Mycophenolate studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Myfortic
- 11
Studies by the year they started
50 studies that test it; most in 2004 (11)
| Year | Studies |
|---|---|
| 2002 | 8 |
| 2003 | 5 |
| 2004 | 11 |
| 2005 | 6 |
| 2006 | 8 |
| 2007 | 3 |
| 2009 | 4 |
| 2010 | 1 |
| 2015 | 1 |
| 2023 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 3
- Phase 3
- 18
- Phase 4
- 28
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 39 · Other 11
Novartis (21) · Novartis Pharmaceuticals (18) · Rafic Farah, MD (1) · University of Michigan Rogel Cancer Center (1) · Hospital Universitari Vall d'Hebron Research Institute (1) · East Carolina University (1) · Pavan Reddy, MD (1) · University of California, San Francisco (1)
Often tested with
Tested in the same studies.
Tacrolimus (6) · Cyclosporine (4) · Etanercept (3) · Azathioprine (3) · Everolimus (2) · Adalimumab (2) · Certolizumab Pegol (2) · Infliximab (2)
Studies
Open first, then newest update. How each study uses Mycophenolate is read from its arms, and is right about nine times in ten.
Testing it · 50
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as Mycophenolate
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Mycophenolate
- Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsNot yet recruitingPhase 4Zhishui ChenNCT05872568Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Measurement of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Renal Transplant Recipients (MyLife)CompletedPhase 4NovartisNCT00149968Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor SourceCompletedPhase 1Rafic Farah, MDNCT02167958Written as Mycophenolate
- Mycophenolate for Pulmonary SarcoidosisTerminatedPhase 3Medical University of South CarolinaNCT00262132Written as Mycophenolate
- Myfortic or CellCept Gastrointestinal Effects in African American Kidney RecipientsTerminatedPhase 4University of PennsylvaniaNCT00522548Written as Enteric coated mycophenolate sodium
- Measurement of Patient Reported Outcomes in Renal Transplant Patients With and Without Gastrointestinal (GI) Symptoms (PROGIS)CompletedPhase 4Novartis PharmaceuticalsNCT00150007Written as Enteric-coated Mycophenolate sodium (EC-MPS)
- Addition of Etanercept and Extracorporeal Photopheresis (ECP) to Standard Graft-Versus-Host Disease (GVHD) Prophylaxis in Stem Cell TransplantCompletedPhase 2University of Michigan Rogel Cancer CenterNCT00639717Written as mycophenolate (standard GVHD prophylaxis)
- Measurement of Patient Reported Outcomes in Korean Renal Transplant Patients With and Without Gastrointestinal (GI) SymptomsCompletedPhase 4Novartis PharmaceuticalsNCT00529269Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.CompletedPhase 3Novartis PharmaceuticalsNCT00425308Written as Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)
- Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney TransplantationCompletedPhase 4Novartis PharmaceuticalsNCT00239005Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion Based Regimen in de Novo Living Donor Kidney Transplant RecipientsCompletedPhase 4Novartis PharmaceuticalsNCT00537862Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Cyclosporine Microemulsion and Steroids in Pediatric de Novo Renal Transplant PatientsCompletedPhase 4Novartis PharmaceuticalsNCT00154206Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Extension Study of Enteric-coated Mycophenolate Sodium With Short-term or no Steroid Use Compared With Enteric-coated Mycophenolate Sodium With Standard Steroid Therapy in de Novo Kidney RecipientsCompletedPhase 4NovartisNCT00240955Written as Enteric-coated Mycophenolate sodium (EC-MPS)
- A One-year, Open Label Study to Investigate the Safety and the Effect of Enteric-coated Mycophenolate Sodium (EC-MPS) in Combination With Cyclosporine Microemulsion in de Novo Kidney Transplant Recipients.CompletedPhase 4NovartisNCT00154245Written as Enteric-Coated Mycophenolate sodium (EC-MPS)
- Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant PatientsCompletedPhase 4NovartisNCT00239083Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Efficacy and Safety of Enteric-coated Mycophenolate Sodium (EC-MPS) in de Novo Kidney Transplant RecipientsCompletedPhase 4NovartisNCT00238953Written as Enteric-Coated Mycophenolate Sodium (EC-MPS)
- Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate MofetilCompletedPhase 4NovartisNCT00400647Written as Enteric-coated Mycophenolate sodium (EC-MPS)
- Conversion Trial From Mycophenolate Mofetil (MMF) to Enteric-coated Mycophenolate Sodium (EC-MPS) in Stable Transplanted Patients Suffering From Gastrointestinal (GI) Adverse Events While on Mycophenolate Mofetil Therapy (MMF) TherapyCompletedPhase 4NovartisNCT00149942Written as Enteric-coated Mycophenolate sodium (EC-MPS)
See all 50 studies that test Mycophenolate →
Given in every arm · 12 — Mycophenolate is usual care beside what is tested
- A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsRecruitingPhase 3Bristol-Myers SquibbNCT04877288Written as Enteric Coated Mycophenolate Sodium
- Outcomes of Patients After Allo-HSCT With Decitabine and NACNot yet recruitingPhase 3The First Affiliated Hospital of Soochow UniversityNCT04945096Written as Mycophenolate
- BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)Active, not recruitingPhase 2SanofiNCT05156710Written as Mycophenolate
- Belatacept Compared to Tacrolimus in Deceased Donor Renal Transplant RecipientsCompletedPhase 4Columbia UniversityNCT02152345Written as Mycophenolate
- Zevalin-Containing Nonmyeloablative Conditioning for Stem Cell Transplantation (SCT)CompletedPhase 2M.D. Anderson Cancer CenterNCT01490723Written as Mycophenolate
- A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) RecipientsCompletedPhase 4Novartis PharmaceuticalsNCT00862979Written as Enteric coated mycophenolate sodium (EC-MPS)
- Efficacy and Safety of a Reduced Immunosuppression vs. Standard Triple Therapy in Senior Renal Transplant RecipientsStatus unknownPhase 4Klemens BuddeNCT02453867Written as mycophenolate
- Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.TerminatedPhase 4Novartis PharmaceuticalsNCT00332839Written as Enteric Coated - Mycophenolate Sodium (EC-MPS)
- Efficacy and Safety of Everolimus+EC-MPS After Early CNI Elimination vs EC-MPS +Tacrolimus in Renal Transplant RecipientsCompletedPhase 4Novartis PharmaceuticalsNCT00965094Written as Enteric Coated Mycophenolate Sodium (EC-MPS)
- Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant RecipientsCompletedPhase 4Novartis PharmaceuticalsNCT00634920Written as Enteric Coated Mycophenolate Sodium (EC-MPS)
- Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant PatientsCompletedPhase 4NovartisNCT00154310Written as Enteric-coated mycophenolate sodium
- Efficacy and Safety of Enteric-coated Mycophenolate Sodium and Cyclosporine in Combination With and Without Steroids, in Adult Renal Transplant RecipientsCompletedPhase 3NovartisNCT00413920Written as Enteric-coated mycophenolate sodium (EC-MPS)
As the comparator · 7 — what is tested is compared with Mycophenolate
- Prevention of Skin Cancer in High Risk Patients After Conversion to a Sirolimus-based Immunosuppressive ProtocolTerminatedPhase 4Charite University, Berlin, GermanyNCT00866684Written as Mycophenolate
- Baricitinib for the Treatment of Ocular Mucous Membrane PemphigoidTerminatedPhase 2Washington University School of MedicineNCT05263505Written as Mycophenolate
- Comparison between2 Drugs in Lupus NephritisCompletedPhase 4Al-Azhar UniversityNCT04424602Written as mycophenolate
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant PatientsCompletedPhase 3Novartis PharmaceuticalsNCT01843348Written as Enteric Coated Mycophenolate Sodium (EC-MPS)
- Tacrolimus/Everolimus Versus Tacrolimus/Enteric-Coated Mycophenolate SodiumCompletedPhase 3Gaetano CiancioNCT01680861Written as Enteric Coated Mycophenolate Sodium (EC-MPS)
- Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant PatientsCompletedPhase 4Associação Médico Espírita de BotucatuNCT02683291Written as mycophenolate
- Evaluation of Early Use of Everolimus (EVE) on Cytomegalovirus (CMV) Infection in Renal Transplant RecipientsStatus unknownPhase 4Fundação Pró RimNCT01927588Written as Mycophenolate+Tacrolimus+Prednisone